On June 1, 2026, Equillium, Inc. (Nasdaq: EQ), a biotechnology company focusing on developing treatments for severe autoimmune and inflammatory conditions, disclosed the granting of an inducement award by its Compensation Committee. This award comprised nonstatutory stock options allowing the purchase of 145,000 common shares to a newly hired individual under Equillium’s 2024 Inducement Plan. The stock option was approved as a significant inducement for the employee's recruitment, following Nasdaq Listing Rule 5635(c)(4).